The discovery of epigenetic processes as possible pivotal regulatory mechanisms in psychiatric diseases raised the question of how psychoactive drugs may impact the epigenetic machinery. In the present study we set out to explore the specificity and the mode of action of the reported inhibitory effect of the TCA (tricyclic antidepressant) amitriptyline on DNMT (DNA methyltransferase) activity in primary astrocytes from the rat cortex. We found that the impact on DNMT was shared by another TCA, imipramine, and by paroxetine, but not by venlafaxine or the mood stabilizers carbamazepine and valproic acid. DNMT activity in subventricular neural stem cells was refractory to the action of ADs (antidepressants). Among the established DNMTs, ADs primarily targeted DNMT1. The reduction of enzymatic DNMT1 activity was neither due to reduced DNMT1 expression nor due to direct drug interference. We tested putative DNMT1-inhibitory mechanisms and discovered that a known stimulator of DNMT1, the histone methyltransferase G9a, exhibited decreased protein levels and interactions with DNMT1 upon AD exposure. Adding recombinant G9a completely reversed the AD repressive effect on DNMT1 function. In conclusion, the present study presents a model where distinct ADs affect DNMT1 activity via G9a with important repercussions for possible novel treatment regimes.
INTRODUCTION
Environmental stress represents a crucial factor that triggers and promotes the development of MDD (major depressive disorder) and BPD (bipolar depression). Epigenetic processes are thought to link environmental cues with gene expression changes. Hence they may play a fundamental role in the pathogenesis of these disorders and may constitute a target for novel treatment options [1] .
Epigenetic marks include methylation of cytosine residues within CpG dinucleotides and histone modifications such as methylation or acetylation. In general, DNA methylation represses, whereas histone acetylation activates, gene transcription. Histone methylation might either activate or repress gene transcription depending on the modified residue as well as its combination with other histone marks [2] . DNA methylation and histone modifications are intimately connected with one another and work in concert to regulate gene expression by controlling chromatin structure and the binding of transcription factors to DNA [3] . This functional link is further illustrated by the interaction of enzymes catalysing histone modifications with DNMTs (DNA methyltransferases) [4] . Three DNMT subtypes set DNA methylation marks in mammalian cells, DNMT1, DNMT3a and DNMT3b. DNMT1 is the major DNMT that executes the maintenance of DNA methylation during the S-phase of replication, whereas DNMT3a and 3b are mainly implicated in de novo methylation. However, this specificity appears sometimes relaxed [4] .
Once established during development, DNA methylation patterns were long considered to remain stable in differentiated cells of the nervous system. However, recent studies in rodents prove that DNA methylation changes dynamically in response to various cues, such as psychosocial factors, diet or drug treatment [5] .
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work in animals that provided similar results [9, 10] . Moreover, in a rodent model, chronic ultra-mild stress was shown to result in increased promoter methylation and decreased expression of GDNF (glial cell-derived neurotrophic factor), a neurotrophic factor implicated in stress resilience and depression. DNMT inhibitors or the AD (antidepressant) imipramine induced AD-like effects on behaviour and reversed the effects on DNA methylation and expression of GDNF in these mice [11] . In addition to imipramine, several other treatment strategies for MDD and BPD were shown to decrease DNA methylation in rodent brain cells. The selective serotonin re-uptake inhibitor escitalopram reversed hypermethylation of the P11 gene in a rat model of depression and led to a reduction in mRNA levels of Dnmt1 and Dnmt3a [12] . The histone deacetylase inhibitor VPA (valproic acid) induced genome-wide DNA demethylation in primary neural cells [13] . Moreover, clozapine, sulpiride and VPA diminished methionine-induced hypermethylation of reelin and GAD67 promoters [14, 15] . Finally, electroconvulsive treatment resulted in reduced methylation and increased expression of genes implicated in neurogenesis, including BDNF (brain-derived neurotrophic factor), a candidate gene associated with depression [16, 17] .
We recently showed that the AD AMI (amitriptyline) reduces genome-wide DNA methylation at CCpGG sites and inhibits DNMT activity in primary cortical astrocytes [13] . In the present study, we investigated the specificity and mode of action of AMI's inhibitory effect on DNMT activity in cortical astrocytes, neurons and subventricular NSCs (neural stem cells). We suggest from our findings that distinct ADs affect the activity of the DNMT1 subtype via G9a, unravelling a role for ADs in modulating epigenetic processes.
EXPERIMENTAL

Materials
ADs and mood stabilizers were purchased from Sigma, except for venlafaxine (donation from Wyeth Pharma). The Akt inhibitor [1L6-hydroxymethyl-chiro-inositol-2(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbonate] and Gö 6983 were from Calbiochem. Stock solutions were prepared by dissolving the substances in water or DMSO (carbamazepine, Akt inhibitor and Gö 6983).
Preparation of rat primary astrocytes, neurons and NSCs
Cortical neurons were prepared from embryonic day 18 rat brains (Sprague-Dawley, Charles River). The animals were kept in accordance with the European Communities Council Directive 2010/63/EU. Astrocytic cultures were prepared from postnatal day 1 animals and cultivated as described previously [18, 19] . Before commencement of the treatment, neurons or astrocytes were kept in B27-Neurobasal medium (neurons) or N2-MEM/Ham's F12 medium (astrocytes) for 24 h. For the NSC cultures, slices from the subventricular zone of postnatal day 4 rats were digested with 0.05 % trypsin (Invitrogen), and the dissociated cells were plated at a density of 200 cells/mm 2 . The cultures were maintained in DMEM (Dulbecco's modified Eagle's medium)/Ham's F12 medium (Invitrogen) with 2 % B27 supplement (Invitrogen), 5 mM Hepes (Sigma), 1× insulintransferrin-sodium selenite supplement (Roche), 10 ng/ml bFGF (bovine fibroblast growth factor; Peprotech) and 10 ng/ml EGF (epidermal growth factor; Peprotech). The culture medium was half-renewed every 3-5 days. NSCs were passaged every 2 weeks by direct pipetting, and all the experiments were performed on passage 4-6 NSCs. Neurons were incubated with 0.5 mg/ml MTT reagent in culture medium for 6 h at 37
• C with 5 % CO 2 . Read-out was as described previously [20] .
Flow cytometric analysis of cell-cycle phases
Cortical astrocytes were harvested and washed once with PBS. Fixation and permeabilization of cells was achieved by adding 1 ml of 3.7 % formaldehyde to a suspension of 5×10 6 cells in 1 ml of PBS, followed by incubation on ice for 30 min. Thereafter, the cells were centrifuged at 300 g for 5 min and the cell pellet was resuspended in 100 μl of PBS. Ice-cold 100 % ethanol (200 μl) was added slowly to the cells while gently vortex mixing for further permeabilization. Cells were incubated on ice for 15 min and washed once with PBS. RNA was digested with 200 μl of RNAse A (100 μg/ml in PBS; Sigma) at 37
• C for 30 min. DNA was stained using 200 μl of PI (propidium iodide solution; 100 μg/ml in PBS; Sigma) and then the cells were analysed (Beckman Coulter Epics XL).
Real-time PCR analysis
Total RNA from neural cells was obtained using the NucleoSpin RNA II kit (Macherey-Nagel) according to the manufacturer's instructions. RNA was reverse transcribed with Omniscript Reverse Transcriptase (Qiagen) and random primers (Promega). The LightCycler ® System (Roche Applied Science) and SYBR Green detection (QuantiFast SYBR Green, Qiagen) was used to carry out the relative quantification of Dnmt1,3a and 3b mRNA levels. Hprt (hypoxanthine-guanine phosphoribosyltransferase) mRNA was expressed at similar levels in the different neural cell types and was used for normalization. Annealing was performed at 60
• C. The primer sequences are listed in Table 1 . The efficiency of the PCR was determined for each primer pair. Eqn(1) was used to calculate the relative amounts of Dnmt mRNA:
where x is the relative Dnmt mRNA level, E Dnmt/Hprt is the PCR efficiency for Dnmt/Hprt primers respectively (expressed as %E = E×100 %) and C T Dnmt/Hprt is the number of the threshold cycle of the Dnmt/Hprt PCR respectively.
Protein extracts
Neural cells were harvested by trypsinization (0.05 % trypsin/EDTA in PBS). In the case of nuclear extract isolation, 2×10 6 cells were initially incubated with 100 μl of hypotonic buffer [10 mM Hepes, 10 mM KCl, 0.5 mM EDTA, 0.1 % NP40 (Nonidet P40), 10 % glycerol and 1 mM DTT (dithiothreitol)] containing protease inhibitor cocktail (Sigma) for 10 min on ice. The cell suspension was vigorously mixed for 5 s and centrifuged at 7000 g for 1 min at 4
• C. The nuclear pellet was incubated with nuclear extraction buffer [20 mM Tris/HCl (pH 7.4), 250 mM NaCl, 5 mM EDTA, 0.1 % NP40, 10 % glycerol, 1 mM DTT and protease inhibitor cocktail] on ice for 15 min. During this incubation, samples were vortex-mixed for 5 s every 3 min. Nuclear extracts were obtained by centrifugation at 12 000 g for 10 min at 4
• C. For the salt-extraction series, nuclear pellets were successively incubated with nuclear extraction buffer containing increasing salt concentrations (100-400 mM NaCl).
Total cell extracts subjected to DNMT activity assays were obtained by resuspending 2×10
6 cells in 100 μl of nuclear extraction buffer followed by sonication (output control 3; 3× 10 pulses each), which results in disruption of nuclei. To remove endogenous DNA, samples were incubated with 0.2 bead vol. DEAE sepharose (Sigma) for 20 min at 4
• C. Total cell extracts for Western blot analysis were obtained by lysing cells in a buffer containing 20 mM Tris/HCl (pH 6.8), 0.66 % SDS and 3.33 % sucrose, supplemented with protease inhibitor cocktail (Sigma). Samples were heated at 95
• C for 5 min and sonicated briefly. Protein concentration was measured using the Pierce BCA (bicinchoninic acid) Protein assay kit according to the manufacturer's instruction.
Western blot analysis
Western blot analysis was conducted as previously described [13] . Briefly, proteins were separated by SDS/PAGE (6-12% gel) and electrotransferred on to nitrocellulose membranes at 100 V for 3 h using buffer containing 25 mM Tris, 190 mM glycine, 30 % methanol and 0.1 % SDS. ECL (enhanced chemiluminescence) detection reagent (Millipore) was applied to visualize the immunoreactive bands. G9a immunoreactive bands ( Figure 8C ) were quantified using the FUSION FX7 system (Vilber Lourmat). The following primary antibodies were used: anti-DNMT1 (1:2000 dilution; catalogue number IMG-261A, Imgenex), antiDNMT3a (1:1000 dilution; catalogue number. IMG-268A, Imgenex), anti-G9a (1:1000 dilution; catalogue number 3306S, Cell Signaling Technology), anti-NAA10 (N-α-acetyltransferase 10; 1:2000 dilution; catalogue number SAB2100142, Sigma), anti-actin (1:2000 dilution; catalogue number A2066, Santa Cruz Biotechnology) and anti-HSC70 (heat-shock cognate 70; 1:2000 dilution; catalogue number sc-7298, Santa Cruz Biotechnology).
Co-immunoprecipitation
Protein extracts were obtained by incubating cells in lysis buffer [10 mM Tris/HCl (pH 7.4), 250 mM NaCl, 0.5 mM EDTA, 0.5 % NP40 and protease inhibitor cocktail (Sigma)] for 20 min at 4
• C with constant mixing. Lysates were cleared by centrifugation (12 000 g for 15 min at 4
• C). Protein extract (1 mg) was diluted in lysis buffer containing 120 mM NaCl to a final volume of 1 ml and incubated with 4 μg of anti-G9a antibody (catalogue number PP-A8620A-00, Perseus Proteomics) for 6 h at 4
• C with constant mixing. Subsequently, Protein G-coated magnetic beads (30 mg/ml; Dynabeads Protein G, Invitrogen) were added and incubated for 2 h at 4
• C. Beads were washed four times with PBS (Invitrogen), and bound proteins were eluted by incubation with 50 μl of elution buffer [80 mM Tris/HCl (pH 6.8), 20 % glycerin, 2.5 % SDS and 2.5 % 2-mercaptoethanol) for 15 min at 70
• C. • C. When poly(dI-dC)·(dIdC) was used, 4 μg of protein extract was applied compared with 10 μg when hemi-/un-methylated DNA was used. The DNMT reaction was stopped at 65
• C for 15 min. Thereafter, DNA substrate was purified and tritium incorporation was measured by scintillation counting. In the case of the DNMT assays supplemented with purified G9a, nuclear extracts (0.7 μg/μl of total proteins in 90 μl) were pre-incubated with vehicle or G9a (catalogue number M0235S, New England Biolabs) and 160 μM unlabelled SAM for 30 min at 37
• C. Subsequently, unreacted SAM was removed using Bio-Spin 6 columns (BioRad Laboratories) and the DNMT assay was conducted as described above. Purification of the DNA substrate was preceded by digestion of proteins using Proteinase K (Sigma).
Purification of the poly(dI-dC)·(dI-dC) substrate
The DNA substrate poly(dI-dC)·(dI-dC) was isolated using the GeneClean kit (MP Biomedicals) following the manufacturer's protocol with minor modifications. Four washing steps were carried out and DNA was bound to glass milk in the presence of a 1000× excess of unlabelled SAM to the lower background signals. In order to achieve maximal DNA recovery, 1 μg of carrier genomic DNA per sample was added to the binding buffer.
Preparation and purification of hemi-/un-methylated substrate DNA Equal amounts (20 μM) of complementary single-stranded biotinylated oligonucleotides were mixed, heated for 5 min at 95
• C and gradually cooled to room temperature (25 • C; 1 h). To generate un-or hemi-methylated DNA, the oligonucleotides 5 -gatctcgtcgtcgcgcgcgcgtcgtcgtcggatc-3 and biotin-5 -gatccgacgacgacgcgcgcgcgacgacgagatc-3 or biotin-5 -gatcmgamgamgamgmgmgmgmgamgamgagatc-3 (where m is 5-methyl-2-deoxycytosine) were mixed. Subsequently to the DNA methyl transfer reaction, biotinylated hemi-/un-methylated DNA was isolated using streptavidin-coated magnetic beads (10 mg/ml Streptavidin; Dynabeads M-280, Invitrogen). Magnetic beads were washed three times and adjusted to a final concentration of 2.5 mg/ml in binding buffer [20 mM Tris/HCl (pH 8.0), 0.2 mM EDTA, 0.01 % Triton X-100 and 1.5 M NaCl] containing 3.2 mM unlabelled SAM. A bead suspension (50 μl) was added to each sample and incubated for 15 min at room temperature with gentle rotation. Magnetic beads were separated by a magnet and washed seven times with 200 μl of wash buffer [10 mM Tris/HCl (pH 8.0), 0.1 mM EDTA, 0.005 % Triton X-100 and 1 M NaCl]. Thereafter, the beads were incubated with 10 units of Dnase I (Roche) in buffer containing 40 mM Tris/HCl (pH 7.9), 10 mM NaCl, 6 mM MgCl 2 and 1 mM CaCl 2 at 37
• C for 20 min. Beads were separated on a magnet and the supernatant was subjected to scintillation counting.
Dialysis
Astrocytic protein extracts (100 μl) were dialysed at 4
• C using cellulose tubing (BioMol) with a pore size of 25 Å (1 Å = 0.1 nm;
Figure 1 Differential effect of psychoactive drugs on DNMT activity in astrocytes
Rat primary cortical astrocytes were treated with the respective drug for 72 h. Nuclear extracts were prepared and incubated with the DNA substrate poly(dI-dC)·(dI-dC) and the methyl group donor 12-16 kDa cut off) against the DNMT assay buffer [20 mM Tris (pH 7.8), 10 % glycerol, 5 mM EDTA, 1 mM DTT and 0.2 mM PMSF] which was renewed every 30 min for a total of three times.
Statistics
At least three independent experiments were performed for all of the DNMT activity assays and Western blots. In the case of Western blot analysis signals were normalized to actin/HSC70 immunoreactivity. The signal from each control extract was divided by the mean of all control extract measurements, and the signal from treatments was divided by the mean of the signals of the respective controls. Significance was analysed between treatment and the respective control groups using Student's t test.
RESULTS
Psychoactive drugs differentially affect DNMT activity
The initial observation that AMI reduces DNMT activity in primary cortical astrocytes [13] prompted us to screen additional ADs including imipramine, venlafaxine, citalopram and PAR (paroxetine) as well as the mood stabilizers carbamazepine and VPA for their effect on DNMT activity. As guidance for the drug concentrations in the assays we used reported therapeutic plasma levels together with the observed accumulation of ADs in the brain. For example, AMI, venlafaxine and PAR accumulate in the murine brain 7-12-fold compared with plasma levels 2-5 h post-administration [21, 22] . Magnetic resonance spectroscopy revealed steady-state concentrations of fluvoxamine and fluoxetine/norfluoxetine in the brain of 12 μM and 13 μM respectively, about 10 times higher than in the plasma [23] ; another study reported similar steady-state levels in the brain (4-37 μM), which were reached after 30-50 days of treatment, the time usually required for the onset of clinical improvement [24] .
Cortical astrocytes were treated with ADs (10 μM) or the mood stabilizers carbamazepine (100 μM) and VPA (10 mM) for 3 days. Proteins were extracted from nuclei and DNMT activity was assayed using poly(dI-dC)·(dI-dC) as the DNA substrate ( Figure 1 ). In addition to AMI, the TCA (tricyclic AD) imipramine, as well as the selective serotonin re-uptake inhibitor PAR, decreased DNMT activity by ∼ 50 %, whereas citalopram also showed a trend in this direction. In contrast, the selective serotonin/noradrenaline re-uptake inhibitor venlafaxine did not impact DNMT activity, and neither did the mood stabilizers carbamazepine or VPA. Together, ADs differentially affect DNMT activity in cortical astrocytes.
Inhibition of DNMT activity is indirect and cell-type specific
To obtain a dose-response relationship, astrocytes were treated with different concentrations of AMI (Figure 2A) . Although 1 μM AMI exerted no effect and a trend was observed with 5 μM AMI, DNMT activity was significantly diminished upon treatment with 10 μM AMI. Previous studies applying radiolabelled drugs provided evidence that ADs readily enter the cytoplasm and nucleus of rodent brain cells [25, 26] . Thus, in addition to their effects on membrane neurotransmitter transporters and receptors, ADs may act directly on cytoplasmic or nuclear proteins. To investigate whether AMI inhibits DNMT activity directly, nuclear extracts from primary astrocytes were incubated with 10 μM AMI for 0.5 h and then assayed for DNMT activity ( Figure 2B ). As the DNMT activity was unchanged in these extracts, we excluded a direct hindrance of the enzyme by AMI. Accordingly, a timecourse analysis revealed a significant inhibition of DNMT activity after 72 h of AMI treatment, but not after 24 and 48 h ( Figure 2C ).
Neurons and presumably NSCs are primary targets of AD action [27] . We therefore determined DNMT activity in cortical neurons ( Figure 3A ) and subventricular NSCs ( Figure 3B ) which were exposed to AMI or PAR for 72 h at 10 μM (in the case of NSCs) or at 5 μM (in the case of neurons). The lower concentration in the case of neurons was chosen since 10 μM AMI and PAR resulted in compromised cell viability as determined by MTT assay (results not shown). In contrast with astrocytes (Figure 1 ), DNMT activity was not altered in neurons and NSCs on AD treatment. In summary, the inhibition of DNMT activity by AMI is indirect, requires long-term treatment and is cell-type specific.
ADs target the DNMT1 subtype
Next, we elucidated which DNMT subtype was potentially affected by the inhibitory actions of ADs. Since cell-type specific differences were monitored (Figures 1 and 3) , the expression profiles of Dnmt1, 3a and 3b in the respective cell types may point to the DNMT subtype targeted by ADs. Real-time PCR analysis revealed that Dnmt1 and Dnmt3a were transcribed at similar levels in neurons and astrocytes, whereas the mRNA levels in NSCs were about 2.5 times higher (Figure 4) . In neurons and NSCs, Dnmt3b was expressed at 10-20-fold lower levels than Dnmt1/3a. The difference was even more pronounced in astrocytes, with Dnmt3b constituting around 0.25 % of Dnmt1. Therefore we reason that DNMT3b contributed only marginally to DNMT activity in astrocytes and that the observed inhibitory effect was not caused by this subtype.
DNMT1 and DNMT3a were reported to possess different affinities to chromatin [28] . To test whether DNMT1, DNMT3a or both were present in nuclear extracts used for the DNMT activity assay, we isolated nuclei from cortical astrocytes and successively extracted proteins with a buffer containing increasing salt concentrations (100-400 mM NaCl). A lysate fraction containing the remaining proteins past the last extraction step was also included (>400 mM NaCl). The levels of DNMT1 and DNMT3a proteins in the different fractions were measured using Western blot analysis ( Figure 5A ). Whereas the majority of DNMT1 was already extracted with 250 mM NaCl, an immunoreactive signal representing DNMT3a was exclusively detected in the fraction >400 mM NaCl. Hence, previously measured DNMT activity in nuclear extracts of astrocytes mainly stemmed from DNMT1 as nuclear extracts used in the DNMT activity assay were obtained with a buffer containing 250 mM NaCl. To further corroborate this conclusion, we compared DNMT activity on different DNA substrates. DNMT1 clearly prefers hemi-over un-methylated DNA in vitro, whereas DNMT3a favours unmethylated DNA [29] . In agreement with the data from salt extraction, DNMT activity in 250 mM NaCl nuclear extracts was high on hemimethylated, and low on unmethylated DNA ( Figure 5B ). Of note, treatment of astrocytes with AMI only resulted in an inhibition of DNMT activity on hemimethylated, but not unmethylated, DNA substrate ( Figure 5C ). This further suggested that predominantly maintenance DNMT1 activity is affected by AD treatment.
Furthermore, DNMT activity assays in total cell extracts from AMI-treated astrocytes also provided no evidence for DNMT3a as a target for AD. When poly(dI-dC)·(dI-dC) was used as a substrate for DNMT1 and DNMT3a, activity was reduced to 46 % ( + − 1 %) of the control extracts ( Figure 5D ), which is similar to the reduction in nuclear extracts (52 + − 6 %). In contrast, DNMT activity was unchanged on unmethylated DNA as a preferred substrate for DNMT3a. In conclusion, AD treatment inhibits DNMT1, whereas no evidence was found for a decrease in DNMT3a activity.
DNMT1 protein levels are unaffected by ADs
The decrease in DNMT1 activity may be due to its diminished expression. Since DNMT1 expression is regulated during the cell cycle [30] , we first analysed whether AMI or PAR treatment alters cell-cycle parameters in astrocytes. The cell-cycle stages of AMIand PAR-treated astrocytes (10 μM, 72 h) were investigated by PI staining/FACS ( Figure 6A ). The percentage of cells in S-+ G 2 -phase was very low in the control cells (∼ 8 %) and did not differ compared with drug-treated cells (∼ 7-8 %). As the inhibitory effect on DNMT activity was observed in nuclear (250 mM NaCl) and total extracts, we subjected both types of extracts to expression analysis using Western blotting ( Figure 6B ). DNMT1 expression levels remained unchanged in both the total and nuclear extracts on AD treatment (10 μM each, 72 h).
Figure 5 AD treatment inhibits DNMT1
(A) Proteins from astrocytic nuclei were successively extracted with a buffer containing increasing NaCl concentrations (100-400 mM). The fraction >400 mM NaCl contains all proteins past the last extraction step. Fractions were probed for DNMT1 and DNMT3a immunoreactivity using Western blot analysis. (B) Nuclear extracts of untreated astrocytes obtained by extraction with 250 mM NaCl show major DNMT activity on hemimethylated and only minor activity on unmethylated oligonucleotides. DNMT activity is shown relative to the mean of the signal from hemimethylated DNA substrate. (C) DNMT activity of nuclear extracts from AMI-treated (10 μM, 72 h) cortical astrocytes was determined using hemimethylated and unmethylated DNA substrate. Controls were set to 1. (D) DNMT activity of total cell extracts from astrocytes treated with 10 μM AMI for 72 h was analysed. Poly(dI-dC)·(dI-dC) or unmethylated oligonucleotides served as DNA substrate. Controls were set to 1. Results are means + − S.E.M. of the relative DNMT activity (n = 3; **P 0.005 and ***P 0.0005 compared with the control). CO, control; HEMI, hemimethylated DNA substrate; n.s., not significant; UN, unmethylated DNA substrate.
ADs inhibit DNMT1 activity through modulation of G9a protein levels
Several factors are known to modulate DNMT1 activity. These include post-translational modifications, SAH (S-adenosylhomocysteine) and protein-interaction partners. To obtain insights into the mechanism of DNMT1 inhibition we analysed the role of these factors in AD-treated cells in greater detail. Post-translational modifications that were shown to impact DNMT1 activity are SUMOylation, exhibiting a stimulatory effect, and phosphorylation of DNMT1 by Akt and PKC (protein kinase C) or PKC alone, conferring an inhibitory effect [31] [32] [33] . First, we found no evidence for a change in DNMT1 SUMOylation using Western blot analysis (results not shown). Secondly, astrocytes were exposed to AMI (10 μM, 72 h) in combination with an PKC inhibitor or Akt and PKC inhibitors including a pre-treatment period with inhibitors for 2 h (0.5 μM Gö 6983) or for 4 days (0.5 μM Gö 6983 and 0.1 μM Akt inhibitor; as according to Hervouet et al. [31] ) respectively ( Figure 7A) . We also included a treatment with the MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellularsignal-regulated kinase) 1/2] inhibitor U0126 (2 μM, 72 h, pretreatment for 2 h) as the impact of ADs on the MAPK signalling pathway is substantiated by several studies [34] [35] [36] . Analysis of DNMT activity showed that blockage of the respective pathways did not reverse the inhibitory action of AMI. Data from in vitro studies suggest that CDKL5 (cyclin-dependent kinase-like 5) phosphorylates DNMT1 [37] . There is a potential link between the regulation of Cdkl5 mRNA, which is shown to be down-regulated by MeCP2 (methyl CpG-binding protein 2) binding, and ADs, which were found to increase MeCP2 protein [38, 39] . Analysis of CDKL5 mRNA levels did not reveal any changes after AMI treatment (10 μM, 72 h; results not shown).
During the process of DNA methylation, the co-factor and methyl group donor SAM is demethylated and converted into the metabolite SAH. SAH in turn feeds back to DNMTs and inhibits the enzymatic activity [40] . To test the hypothesis that the inhibitory effect of ADs is based on elevated SAH levels, we removed SAH from the nuclear extracts of AMI exposed astrocytes by dialysis ( Figure 7B ). There was no difference in the extent of inhibition when dialysed extracts were compared with non-dialysed extracts. NAA10 and the histone methyltransferase G9a are interaction partners of DNMT1 and were found to regulate its enzymatic activity in vitro [41, 42] . Whereas NAA10 levels were not reduced after treatment with 10 μM AMI/PAR for 72 h, G9a levels were diminished in both the total and nuclear extracts as determined by Western blotting. In contrast, carbamazepine, which has a similar structure to AMI, but did not reduce DNMT activity, did not affect G9a levels ( Figure 8A ). Of note, after 24 or 48 h of AMI exposure, where no effect on DNMT activity was detected ( Figure 2C ), also no reduction in G9a levels was observed ( Figure 8B) . If the reduction of G9a levels was responsible for the effect of AMI on DNMT, it should be reversed by addition of G9a to the extracts. Therefore we supplemented nuclear extracts with recombinant G9a and monitored DNMT1 activity ( Figure 8C) . Remarkably, when 125 pg of G9a per μg of protein lysate was added, DNMT1 activity was recovered to the levels of the control cells. Addition of the same amount of G9a to the control extracts showed no significant enhancement of DNMT1 activity. Western blot analysis, in which a standard curve with purified G9a was included, revealed that extracts derived from AMI-treated cells supplemented with purified G9a were exposed to about ∼ 7-fold higher levels of G9a as compared with the controls ( Figure 8C ). The addition of a significantly larger amount of recombinant G9a (1.25 ng of G9a per μg of protein lysate) resulted in a marked increase (12-and 7-fold) in DNMT1 activity in extracts from the control and AMI-treated cells (Supplementary Figure S1 at http://www.BiochemJ.org/bj/448/bj4480093add.htm). In vitro studies suggest that the enhancing effect of G9a on DNMT1 activity is mediated by a direct interaction between these two enzymes [41] . To test whether the reduced levels of G9a upon treatment with AMI also result in a reduction of G9a-DNMT1 interactions, co-immunoprecipitation experiments were conducted. Indeed, immunoprecipitation in extracts derived from AMI-treated cells yielded not only significantly less G9a, but also smaller amounts of co-precipitated DNMT1 ( Figure 8D ). In contrast, when extracts from AMI-treated cells were supplemented with recombinant G9a, a reduction in the amount of co-precipitated DNMT1 was not detectable. 
Figure 8 G9a mediates the inhibition of DNMT1 activity by ADs
Cortical astrocytes were treated with 10 μM AMI/PAR or 100 μM CBZ for 72 h (A) or 10 μM AMI for 24, 48 or 72 h (B). Relative G9a or NAA10 protein levels in total (A) or nuclear extracts (A and B) were determined using Western blot analysis. HSC70 or actin served as housekeeper proteins. (C) Nuclear extracts (250 mM) from astrocytes treated with 10 μM AMI for 72 h were supplemented with 500 pg of recombinant G9a (rec. G9a) or vehicle and DNMT activity was measured. G9a immunoreactive signals of a concentration series of recombinant G9a and nuclear extracts from control/AMI-treated astrocytes are shown. Actin served as a housekeeper. (D) Astrocytes were treated with 10 μM AMI for 72 h. Interaction between G9a and DNMT1 was assessed by co-immunoprecipitation (CoIP) using an anti-G9a antibody. Results are means + − S.E.M. (n 3; *P 0.05). AU, arbitrary units; CO, control; CBZ, carbamazepine; IP, immunoprecipitation; n.s., not significant.
DISCUSSION
The prevailing view of the mode of action of ADs suggests that they modulate monoaminergic neurotransmission. However, there is growing evidence that additional targets of ADs exist, including epigenetic factors. In the present study, we demonstrated that treatment of cortical astrocytes with various ADs, such as the TCAs AMI and imipramine, as well as the selective serotonin reuptake inhibitor PAR, reduces the enzymatic activity of DNMT1, an enzyme implicated in the initiation and maintenance of methylation marks. There was no evidence for a comparable drug effect on DNMT1 activity in neurons or NSCs. Nevertheless, we cannot exclude the possibility that under different settings DNMT1 in these cell types also reacts to ADs, for example when glial-neuron interactions are operative. Furthermore, increasing evidence suggests that glial dysfunction contributes to the pathophysiology and presumably pathogenesis of MDD. Studies on post-mortem brain tissue from patients showed reduced glial cell numbers in cortical brain regions [43] . Conversely, pharmacological ablation of glial cells in the prefrontal cortex evokes depressive-like behaviour in rats [44] . Forming an integral part of tripartite synapses, astroglial cells play a crucial role in synaptic function and plasticity [45] . Hence, altered neuronal communication, as observed in MDD, may at least in part result from compromised astrocytic function.
A series of biochemical and cellular analyses pointed to DNMT1 as a cellular target of AD actions and ruled out the de novo methyltransferases DNMT3a and DNMT3b. Importantly, we observed that DNMT1 activity was altered through an indirect mechanism that involved reduced protein levels of the histone methyltransferase G9a, a known modulator of DNMT1. G9a has been characterized as transcriptional silencer by executing mono-, di-and tri-methylation of euchromatic H3K9 (histone 3 Lys 9 ) as well as by promoting DNA methylation [46] . The present study reveals that G9a is a target of AMI and PAR. Moreover, the fact that the reduction in G9a protein levels coincided with the decrease in DNMT activity indicated a functional impact of G9a on DNMT1 operations. It has previously been demonstrated that DNMT1 directly binds to G9a. This interaction significantly enhanced the catalytic activity of recombinant DNMT1 in vitro, in the absence of any other proteins [46, 41] . Furthermore, regulation of DNA methylation by G9a is independent of its catalytic activity, implying that its physical presence, but not H3K9 methylation or methylation of DNMT1, is relevant [47] . Therefore the stimulatory effect of G9a either involves the induction of a conformational change of DNMT1 or facilitates its targeting to DNA, or both. Importantly, the present study shows that stimulatory G9a-DNMT1 interactions restore DNMT1 activity in extracts from AMI-treated astrocytes, a finding that adds strong support for the role of G9a in mediating the actions of ADs. In light of our previous demonstration that treatment of astrocytes with AMI does not reduce global H3K9 dimethylation [13] , it seems plausible that the diminished levels of G9a only affect euchromatic histone methylation. It is important to note that several other histone methyltransferases are involved in H3K9 methylation [48] , potentially serving to attenuate or compensate for deficits in H3K9 methylation.
In contrast with AMI and PAR, VPA, which is often administered as augmentation therapy in depression, did not decrease DNMT activity. However, treatment of NT-2 cells with VPA for 24 h was previously shown to reduce DNMT activity and DNMT1 protein levels [49] . Therefore the effect of VPA on DNMT1 may be cell-type specific and depend on the proliferation status.
A number of animal studies suggest that treatment of depressive-like symptoms may benefit from substances reducing DNMT activity. Infusion of both nucleoside and nonnucleoside DNMT inhibitors into the brain regions implicated in depression, including the ventral striatum, the hippocampus and the nucleus accumbens, mediates AD-like effects in diverse behavioural tests [50, 11] . The reason for the effectiveness of DNMT inhibitors in non-cycling cells most likely relies on the dynamic nature of cytosine methylation. Highly dynamic and reversible DNA methylation has previously been observed also in differentiated neural cells [51, 52] . Hence, a reduction of DNMT activity may result in slower or insufficient remethylation, and this may ultimately lead to altered gene expression. Notably, antidepressive-like behaviour in rodents triggered by administration of DNMT inhibitors is accompanied by reduced methylation and increased expression of Bdnf , a gene that is considered to play a role in depression [50] . Furthermore, we previously showed that treatment of astrocytes with AMI reduces genome-wide DNA methylation at CCpGG sites which are frequently enriched in CpG islands of gene promoters [13] . Interestingly, high levels of whole-genome 5-methylcytosine were recently demonstrated to be associated with increased behavioural stress-reactivity subsequent to early life stress in bonnet macaques [53] .
The concept that the establishment of aberrant DNA methylation patterns might contribute to consolidate the disease state of MDD and related disorders has received wide attention. In this respect, we submit that ADs not only act on membrane transporters and receptors, but also interfere with certain parts of the epigenetic machinery, namely DNA modifying enzymes. In this way, ADs may participate in chromatin remodelling and alleviate the disease state by re-establishing transcriptional homoeostasis.
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